Home  |  Site Map  |  Glossary  | Contact
JAN. 5

QLT to Appoint Glen Ibbott as Interim Chief Financial Officer

dec. 16

QLT Announces Results of Annual General Meeting of Shareholders

Provides Update on Strategic and Business Review

dec. 5

QLT Announces Results from Proof-of-Concept Trial with Oral Synthetic cis-Retinoid (QLT091001) in Adult Subjects with Impaired Dark Adaptation and/or Impaired Low Luminance Vision

dec. 2

QLT Announces Departure of Chief Financial Officer

  2014 Proxy Materials and Annual Report
For the 2014 Proxy Statement and Annual Report for the fiscal year ended December 31, 2013, click here
Sept. 13

Vision Improvement After Retreatment with an Oral Synthetic cis-Retinoid (QLT091001) in Subjects with Inherited Retinal Disease caused by Mutations in RPE65 or LRAT

Copyright 2000-2009 QLT Inc. Legal Terms for use of site and Privacy Policy | Disclaimer
Vancouver Web Design by Graphically Speaking
Employee Login